



Euro *Hybrid* Forums

European Forum

Thurs. 15 Sept.

Principe di Savoia

Milan, Italy

European Programme

2022

Alcon

We Help People See Brilliantly.

At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Each year our products touch the lives of millions of people living with conditions like cataracts, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

At Alcon, we are at the forefront of innovation, partnering with eye care professionals to bring the gift of sight to more people around the world. That's been our legacy for more than 70 years—and as the new Alcon, it's what guides our focus towards the brilliant future ahead.

Learn more at alcon.com

CONNECT WITH US!

 [@AlconEyeCare](#)
[@AlconCareers](#)

 [@Alcon](#)

 [@AlconLife](#)

Welcome: EUROPEAN HYBRID FORUM

Welcome to Ophthalmology European Forum 2022.

After virtual meetings in 2020 and 2021, we are pleased to be back in Milan for an in-person event on the 10 th Anniversary of Ophthalmology Futures Forums which, coincidentally, will be held in the very same venue as our first OF Forum in 2012. Our universe has certainly changed in many ways over the past two years, perhaps no greater than in how people communicate information. While it would be wonderful to have every attendee join us in Milan, we realize this is not possible and thus there will be a virtual component to the meeting for those who prefer to participate remotely from other locations in Europe and the rest of the world.

Ophthalmic innovation remains robust and we have been pleased to receive a record number of company applications of which 32 have been selected to present at the 2022 Forum. Our 8 panels, which feature an all-star cast of leaders and stakeholders will cover advances in Cataract Surgery, Corneal Disease, Drug Delivery, Glaucoma Surgery as well as the global burden of Myopia. As in prior years, we will discuss the business of ophthalmic innovation and present a Shark Tank award to conclude the day. We are confident that you will enjoy the formal program as well as the networking opportunities that come with an in-person event. Ophthalmology Futures Forums would like to thank our key advisors, corporate presenters and distinguished faculty for their invaluable support and assistance. We would also like to especially thank our sponsors who have provided support allowing us to keep registration costs low for all attendees!

Thank you for joining us in Milan!

Keith Barton and Kuldev Singh
on behalf of the Ophthalmology Futures Team



Vision Futures Limited, London, UK.
Registered in England No: 8125858.

Timings:

EUROPEAN HYBRID FORUM

TIMMINGS ARE IN CENTRAL EUROPEAN SUMMER TIME

7:45 - 8:20

REGISTRATION

8:20 - 8:30

WELCOME

- Keith Barton & Kuldev Singh

8:30 - 8:40

MARKET OVERVIEW

- Michael Giaquinto

8:40 - 9:10

DRUG DELIVERY FOR OCULAR DISEASE: HAS THERE BEEN PROGRESS?

PANEL

- Colin Francou
- Doug Hubatsch
- George Ousler
- Marcos Rivas
- Michael Goldstein
- Parisa Zamiri

CO-CHAIRS

- Eugene de Juan & Keith Barton

9:10 - 10:10

COMPANY PRESENTATIONS 1

- Polyactiva | Vanessa Waddell
- EYE-GO A/S | Henrik Nagel
- Eyenovia | Beth Scott
- Max Biology | Sunil Shah
- Ocuphire Pharma | Mina Sooch
- Tarsier Pharma | Ruti Friedel
- IVERIC Bio | Dhaval Desai
- Novartis Pharma AG | Michela Montecchi-Palmer

10:10 - 10:40

WILL CORNEAL ENDOTHELIAL CELL IMPLANTATION AND OTHER NOVEL APPROACHES MAKE KERATOPLASTY PROCEDURES OBSOLETE?

PANEL

- Almog Aley-Raz
- Greg Kunst
- Laura de Benito-Llopis
- Nahum Ferera
- Shigeru Kinoshita

CO-CHAIRS

- Jodhbir Singh Mehta & Mor Dickman

10:40 - 11:10

NETWORKING BREAK

11:10 - 12:20

COMPANY PRESENTATIONS 2

- EyeYon Medical | Sharon Bakalash
- CorNeat Vision | Almog Aley-Raz
- Nicox Ophthalmics, Inc. | Doug Hubatsch
- Vialase, Inc. | Shawn O'Neil
- ELIOS Vision | Cameron Hudson
- iStar Medical | Michel Vanbrabant
- Sanoculis Ltd. | Nir Israeli
- Ciliatech | Olivier Benoit

12:20 - 12:50

THE FUTURE OF MIGS - WHAT COMES NEXT?

PANEL

- Andrew Geddes
- Antonio Fea
- Cameron Hudson
- Leon Herndon
- Omar Sadruddin
- Shawn O'Neil
- Stefan Uhrlandt

CO-CHAIRS

- Norbert Pfeiffer & Stefano Gandolfi

12:50 - 13:40

NETWORKING LUNCH

13:40 - 14:10

IS THE EMERGENCE OF THE OPHTHALMOLOGIST INVESTOR IN EYE COMPANIES GOOD OR BAD FOR MEANINGFUL INNOVATION WITHIN THE ECOSYSTEM?

PANEL

- Andrew Chang
- Ehsan Sadri
- Laurent Attias
- Richard Lindstrom

CO-CHAIRS

- Elizabeth Yeu & Sheraz Daya

14:10 - 14:40

THE IMPACT OF INFLATION AND MARKET CORRECTION ON OPHTHALMIC INNOVATION

PANEL

- Charles Hess
- Jeannette Bankes
- Warren Foust
- William Link

CO-CHAIRS

- Kuldev Singh & Stuart Raezman

14:40 - 15:40

COMPANY PRESENTATIONS 3

- Medevis Consulting | Kristine Morrill
- Thea Open Innovation | Colin Francou
- Overture | Duncan Welling
- Inifinte Medical Ventures | Sheraz Daya
- Machine MD | Dominc Senn
- Dive Medical | Alejandro Noceda
- Novasight Ltd. | Ran Yam
- Blink Energy | Yariv Baron

15:40 - 16:10

NETWORKING BREAK

16:10 - 16:50

THE GLOBAL PUBLIC HEALTH PROBLEMS OF MYOPIA: IS SURGERY A SERIOUS COMPETITOR TO NON-SURGICAL OPTIONS?

PANEL

- Ashiyana Nariani
- Charles Williamson
- Dirk Muehlhoff
- Franck Leveiller
- Olga Prenat
- Osama Ibrahim
- Xiao-Yu Song

CO-CHAIRS

- Arthur Cummings & Mark Bullimore

16:50 - 17:30

COMPANY PRESENTATIONS 4

- Dopavision | Mark Wuttke
- Allotex, Inc. | Michael Mrochen
- Photon Therapeutics Ltd. | Sunil Shah
- Acufocus, Inc. | Yari Mitchell
- Excel-Lens, Inc. | David Mordaunt

17:30 - 18:00

BIOTECH VS MEDTECH RETURN IN INVESTMENT IN OPHTHALMOLOGY

PANEL

- Alex Pasteur
- Dmitrij Hristodorov
- Florian Muellershausen
- Katya Smirnyagina
- Michael Giaquinto
- Tiziana Rossetti

CHAIR

- Nik Economopoulos

18:00 - 18:30

PHACO INSTRUMENTATION: HAS THE TECHNOLOGY PEAKED OR WILL WE SEE DISRUPTIVE CHANGE IN THE 2020'S?

PANEL

- David Spalton
- Leonard Borrmann
- MK Raheja
- Samuel Masket
- Seba Leoni
- Sunil Shah
- Thorsten Tritschler

CO-CHAIRS

- Gerd Auffarth & David Chang

18:30 - 19:25

COMPANY PRESENTATIONS 5 - THE SHARK TANK

MODERATOR

- Keith Barton

PREY

- Greg Kunst | Aurion Biotech
- Lisa Kleintjens | IMCustomeye
- Pablo Artal | Voptica S.L.

SHARKS

- Florian Muellershausen
- Laurent Attias
- Nik Economopoulos
- Tiziana Rossetti

VOTE AND AWARD

19:25 - 19:30

SUMMARY AND CONCLUDING COMMENTS

CO-CHAIRS

- Keith Barton and Kuldev Singh

19:30 - 20:30

COCKTAIL RECEPTION

Sponsored by Radiance Therapeutics

SAVE THE DATES EURO FORUMS

European Forum: Vienna
Thurs. 7 September

Retina Forum: Amsterdam
Weds. 4 October

ophthalmology-futures.com



EssilorLuxottica is proud to
support the Ophthalmology
Futures Forums 2022.

Join the panel on myopia to learn more
about the future of myopia management.

<https://www.ophthalmology-futures.com/euro-2022/>

Thursday, 15 September,
16:10 - 16:40 CET

[essilorluxottica.com](https://www.essilorluxottica.com)



REGENXBIO

SEEKING TO
IMPROVE LIVES
THROUGH THE
CURATIVE
POTENTIAL OF
GENE THERAPY

OUR COMMITMENT

REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy using our NAV[®] Technology Platform. Our gene therapy product candidates are designed to deliver functional genes, enabling the production of therapeutic proteins or antibodies that are intended to impact disease.

For the latest updates on our programs, visit [REGENXBIO.COM](https://www.regenxbio.com)

REGENXBIO.com

IVERIC
BIO

TRANSFORMATIVE
THERAPIES
FOR RETINAL DISEASES

Retina is our focus. **Our only focus.**

Geographic Atrophy | Stargardt Disease | Inherited Retinal Diseases

Learn more at [IvericBio.com](https://www.IvericBio.com)

Envisioning the future

NOVARTIS | Reimagining Medicine

Speakers:

PRESENTING COMPANIES

PANNELISTS & CHAIRS

CHAIRS & PANELLISTS

A

- **Almog Aley-Raz**
CEO, Corneat Vision
- **Laurent Attias**
Senior Vice President,
Head of Corporate Strategy, BD&L
and M&A, Alcon
- **Gerd Auffarth**
Chairman, Ruprecht-Karls
University of Heidelberg

B

- **Jeannette Bankes**
President & GM Global
Surgical Franchise, Alcon
- **Keith Barton**
Co-chair, Ophthalmology Futures Forums
- **Leonard Borrmann**
Head of Research & Development,
Centricity Vision, Inc.
- **Mark Bullimore**
Adjunct Professor, University of
Houston College of Optometry

C

- **Andrew Chang**
Global Head of Sales Ophthalmic
Device and President of CZMI, ZEISS
- **David Chang**
Physician, Altos Eye Physicians
- **Arthur Cummings**
Consultant Ophthalmologist,
Wellington Eye Clinic

D

- **Sheraz Daya**
Medical Director, Centre for Sight
- **Eugene de Juan**
Managing Partner, ForSight Labs, LLC
- **Laura de Benito-Llopis**
Consultant Ophthalmologist,
Moorfields Eye Hospital NHS
Foundation Trust
- **Mor Dickman**
University Eye Clinic Maastricht

E

- **Nik Economopoulos**
Associate, Novo Ventures

F

- **Antonio Fea**
Struttura Complessa Oculistica
Università Degli Studi di Torino
- **Nahum Ferera**
CEO and Co-Founder,
EyeYon Medical
- **Warren Foust**
Worldwide president of Surgical
Visoin, Johnson & Johnson Vision
- **Colin Francou**
Managing Director, Thea Open
Innovation

G

- **Stefano Gandolfi**
Professor and Chair,
University of Parma
- **Andrew Geddes**
VP - Commercial Operations Europe,
Middle East, Africa and India,
Glaukos Corporation
- **Michael Giaquinto**
Senior Managing Director, SVB Leerink
- **Michael Goldstein**
President and CMO, Aurion Biotech

H

- **Leon Herndon**
Glaucoma Specialist, Duke Health
- **Charles Hess**
VP & General Manager,
Bausch + Lomb
- **Doug Hubatsch**
Chief Scientific Officer and Head
of R&D, Nicox Ophthalmics, Inc.
- **Cameron Hudson**
SVP, OUS Commercialisation,
ELIOS Vision
- **Dmitrij Hristodorov**
Partner, Forbion

I

- **Osama Ibrahim**
Professor of Ophthalmology,
University of Alexandria,
Faculty of Medicine

K

- **Shigeru Kinoshita**
Professor, Kyoto Prefectural University
of Medicine
- **Greg Kunst**
CEO, Aurion Biotech

L

- **Seba Leoni**
VP, Global Vision Suite, Alcon
- **Franck Leveiller**
CSO, SVP, Head Global Research &
Development, Alcon
- **Richard Lindstrom**
Founder and Attending Surgeon,
Minnesota Eye Consultants
- **William Link**
Managing Director, Versant Ventures

M

- **Samuel Masket**
Clinical Professor, UCLA
- **Jodhbir Singh Mehta**
Professor, Singapore National Eye Centre
- **Dirk Muehlhoff**
Head of Refractive Lasers,
Carl Zeiss Meditec AG
- **Florian Muellershausen**
Principal, Novartis Venture Fund

N

- **Ashiyana Nariani**
Global Clinical Consultant,
King Edward Memorial Hospital

O

- **Shawn O'Neil**
CCO, ViaLase, Inc
- **George Ousler**
Senior Vice President, Anterior
Segment, Ora. Inc

P

- **Alex Pasteur**
Partner, F-Prime Capital
- **Norbert Pfeiffer**
Head of Department
Universitätsmedizin Mainz,
Augenlinik und Poliklinik
- **Olga Prenat**
Head of Medical Marketing and
Professional Relations, Essilor Luxottica

R

- **Stuart Raetzman**
Executive Chairman,
Equinox Ophthalmic Inc.
- **MK Raheja**
VP/Head of R&D, Surgical Vision,
Johnson & Johnson Vision
- **Marcos Rivas**
Global Medial Director, Abbvie
- **Tiziana Rossetti**
Senior Associate, Sofinnova Partners

S

- **Ehsan Sadri**
Founder and CEO,
Visionary Eye Institute
- **Omar Sadruddin**
Senior Medical Director, Glaucoma,
Santen Pharmaceutical Co. Ltd.
- **Sunil Shah**
Consultant Ophthalmology,
Midland Eye
- **Kuldev Singh**
Co-chair, Ophthalmology Futures Forums
- **Katya Smirnyagina**
Senior Partner, Life Sciences,
Oxford Sciences Innovation
- **Xiao-Yu Song**
Global head,
Johnson & Johnson Vision
- **David Spalton**
Consultant Ophthalmic Surgeon

T

- **Thorsten Tritschler**
Head of Product Management
Ophthalmic Surgery Systems, Zeiss

U

- **Stefan Uhrlandt**
R&D VP, iStar Medical

W

- **Charles Williamson**
Founder and Medical Director,
Williamson Eye Center

Y

- **Elizabeth Yeu**
Ophthalmologist,
Virginia Eye Consultants

Z

- **Parisa Zamiri**
CMO, Graybug Vision

PRESENTING COMPANIES

A

- **AcuFocus**
Yari Mitchell,
Mgr. Medical Education
- **Allotex, Inc.**
Michael Mrochen, CEO
- **Aurion Biotech**
Greg Kunst, Vice President

B

- **Blink Energy**
Yariv Baron, CEO

C

- **Ciliatech**
Olivier Benoit, CEO
- **Corneat Vision**
Almog Aley-Raz,
Marketing and Business
Development Coordinator

D

- **Dive Medical**
Alejandro Noceda,
Business Development Manager
- **Dopavision GmbH**
Mark Wuttke, CEO

E

- **ELIOS Vision**
Cameron Hudson, SVP,
OUS Commercialisation
- **EXCEL-LENS, Inc.**
David Mordaunt, President
- **EYE-GO A/S**
Henrik Nagel, Business
Development Director
- **Eyenovia**
Beth Scott, Vice President
- **EyeYon Medical**
Sharon Bakalash, CCO

I

- **iStar Medical**
Michel Vanbrabant, CEO
- **Infinite Medical Ventures**
Sheraz Daya, CEO
- **IVERIC bio**
Dhaval Desai, VP Launch Strategy
- **IMCustomeye**
Lisa Kleintjens

M

- **Machine MD**
Dominc Senn, Managing Director
- **Max Biology**
Sunil Shah, Co-founder
- **Medevis Consulting**
Kristine Morrill, Executive and
Client Projects Assistant

N

- **Nicox Ophthalmics, Inc.**
Doug Hubatsch, CSO and
Head of R&D
- **Novartis Pharma AG**
Michela Montecchi-Palmer,
Global Program Head
- **NovaSight Ltd.**
Ran Yam, CEO

O

- **Ocuphire Pharma**
Mina Sooch, VP, Business
Development and Market Strategy
- **Overture Health**
Duncan Welling, Curation and
Investment Researcher

P

- **Photon Therapeutics Ltd.**
Sunil Shah, CEO
- **Polyactiva**
Vanessa Waddell, Interim CEO

S

- **Sanoculus Ltd.**
Nir Israeli, CEO

T

- **Tarsier Pharma**
Ruti Friedel, Business Development
- **Thea Open Innovation**
Colin Francou, Managing Director

V

- **ViaLase, Inc.**
Shawn O'Neil, CCO
- **Voptica S.L.**
Pablo Artal, CEO

Sponsors: EUROPEAN FORUM 2022

THANKS TO THE GENEROSITY OF OUR SPONSORS, THERE IS NO FEE FOR COMPANY PRESENTATIONS AND VIRTUAL REGISTRATION IS COMPLIMENTARY FOR EVERYONE.

PLATINUM

Alcon

At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Each year our products touch the lives of millions of people living with conditions like cataracts, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

At Alcon, we are at the forefront of innovation, partnering with eye care professionals to bring the gift of sight to more people around the world. That's been our legacy for more than 70 years – and as the new Alcon, it's what guides our focus towards the brilliant future ahead.

GOLD

Apellis

Apellis is a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing medicines.

At Apellis, we are committed to developing transformative therapies for people living with Geographic Atrophy (GA) by regulating complement, a part of the body's immune system.

Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases such as GA, where there are currently no treatment options available.

For more information about Apellis visit apellis.com and if you would like to learn more about geographic atrophy, visit www.geographicatrophy.eu.

SILVER

EssilorLuxottica

EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. Formed in 2018, its mission is to help people around the world to see more and be more by addressing their evolving vision needs and personal style aspirations. The Company brings together the complementary expertise of two industry pioneers, one in advanced lens technology and the other in the craftsmanship of iconic eyewear, to set new industry standards for vision care and the consumer experience around it. Influential eyewear brands including Ray-Ban and Oakley, lens technology brands including Varilux and Transitions, and world-class retail brands including Sunglass Hut, LensCrafters, Salmoiraghi & Viganò and GrandVision are part of the EssilorLuxottica family. EssilorLuxottica has approximately 180,000 employees.

IVERIC BIO

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients' lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

NOVARTIS

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

BAUSCH + LOMB

Each day, we have 14 billion little reminders to continue advancing eye health. From the moment we open our eyes and start to view the possibilities of each new day, we look at how we can improve the well-being of the world's 14 billion eyes. Will this be the day when one of us unlocks a way to eliminate visual impairment in new-borns? Or strikes upon a treatment that actually helps the eye heal itself? To us, these are not some distant hopes. They are the daily questions that add new urgency to all we do and everything we see for the future. We're Bausch + Lomb. One company solely focused on advancing the vision and care of the world's eyes.

REGENXBIO

REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy has the potential to provide long-lasting effects and improved patient outcomes. We have developed a broad pipeline of gene therapy programs using our NAV® Technology Platform. We believe this platform forms a strong foundation for our current programs, and with our ongoing research and development, we expect to continue to expand the platform.

BRONZE



AcuFocus, Inc., is a privately held ophthalmic medical device company that delivers breakthrough small aperture intraocular products to address diverse unmet needs and help patients achieve their best personal vision. The IC-8 IOL is a first-of-its-kind presbyopia-correcting lens that delivers true extended depth of focus and enhanced adaptability through its distinctive, wavefront-filtering, small aperture design. The IC-8 IOL received CE mark in 2015 and is available in select markets across Europe and Asia. Visit www.AcuFocus.com for more information.



Ora is the world's leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom, Ireland, Australia, and Asia, and with personnel across over 25 countries to serve clinical sites locally. For over 40 years, Ora has proudly helped clients across the globe earn over 50 product approvals. Ora's unique methodologies and strategies have been proven to maximize the likelihood of success and efficiently bring new products to market. We bring together the world's most experienced ophthalmic experts and operations management to maximize the value of new product initiatives. For more information, visit www.oraclinical.com.



At Johnson & Johnson Surgical Vision we are passionate about changing the trajectory of eye health and dedicated to partnering with our customers to help more people around the world preserve and restore sight. For over 130 years we have been guided by our CREDO, focusing on improving the lives of the patients and the communities we serve. Our mission is to bring science driven innovation to life through our products and our customer partnerships to elevate eye health for the benefit of all patients. Our commitment to innovation sees us offers a broad range of eye health solutions in ophthalmic care. Our TECNIS® IOL portfolio for example delivers unsurpassed visual outcomes using a combination of proprietary and industry leading optics technologies. We also offer advanced astigmatism management solutions and are a global leader in Refractive Laser Surgery, with an innovative suite of technologies to deliver best in class outcomes.



Théa is the leading independent European pharmaceutical group in ophthalmology. Leader and pioneer in preservative-free treatments, Théa is the unique partner of the eye care professionals for it has constantly been innovating to provide them and their patients with answers to unmet eye care needs. Today, Théa's network includes 1,600 collaborators, and its products are available in 75 countries around the world through its 35 affiliates and partners. In 2021, Théa had global revenues of approximately \$773 million. The independent and family-owned and run group, founded from a R&D start-up by Henri Chibret, has been chaired since 2008 by Jean-Frédéric Chibret. www.laboratoires-thea.com/en



Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease. www.glaukos.com

NEW INNOVATOR



Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to restore vision to millions of patients with our life-changing regenerative therapies. Our first candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells manufactured from a single donor can treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and central corneal thickness. The Aurion Biotech team is preparing for clinical trials in the U.S. To learn more about Aurion Biotech, visit www.aurionbiotech.com



Oculis is a global biopharmaceutical company purposefully driven to save sight, improve eye care and address significant unmet medical needs with breakthrough innovations. Oculis's highly differentiated pipeline includes candidates for topical retinal treatments, topical biologics and disease modifying treatments. With a presence in key international markets, Oculis is poised to deliver life-changing treatments to patients worldwide. Headquartered in Lausanne, Switzerland and with operations in Europe, the U.S. and China, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.



ELIOS Vision, Inc. is a private medical device company headquartered in Los Angeles, CA involved in the commercialisation a novel treatment for glaucoma. The treatment, named ELIOS, safely and effectively lowers IOP and has published outcomes with up to 8yrs of follow-up. ELIOS uses a proprietary laser technology making it reproducible and easy to adopt by comprehensive eye doctors as well as glaucoma specialists. ELIOS is approved for use in EU and is currently undergoing clinical trials for use in the US.



Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for dry eye disease. Nicox generates revenue from VYZULTA® in glaucoma and ZERVIA® in allergic conjunctivitis, both of which are commercialized by partners.



A new name in the ophthalmic industry, Medevis Consulting is composed of individuals with enormous experience in and passion for ophthalmology. Guided by Founder and President Kristine Morrill and our Board of Directors, Medevis exists to help companies realize their full potential in Europe. We offer an array of innovative services that prepare companies to: meet the challenging and complex questions that arise when developing market access, understand clinical and regulatory procedures, and strategically execute marketing and communications initiatives.



iSTAR Medical pioneers minimally invasive, ophthalmic implants for safe, meaningful and sustained treatment of glaucoma patients. MINiject® is the only commercially available supraciliary MIGS device and is made from STAR® material, which is soft and flexible, medical-grade, micro-porous silicone enabling bio-integration of surrounding tissues. Clinical trials show that IOP is reduced by 39% to a mean of 14.4mmHg at two years post-surgery. MINiject received CE marking in late 2021 and the US FDA trial (STAR-V) for MINiject is in progress.



CILIATECH is developing a new class of implant to address the increasing need to treat glaucoma durably and with zero adverse effects. The company's groundbreaking concept CID (Cilio-scleral Interpositioning Device) is the first implant in the industry to reduce IOP without penetrating the anterior chamber or creating subconjunctival filtration. Clinical trials show IOP is reduced by 33% at 12 months (89% patients drop free, no reoperation needed) and without ECL risk.



ViaLase, Inc. is a med-tech, VC backed start-up company focused on disrupting the conventional glaucoma treatment paradigm with the introduction of femtosecond laser technology to enhance glaucoma patient care. The ViaLase team has over 200 years of femtosecond experience bringing femtosecond lasers to Ophthalmology in the refractive market, cataract market and now glaucoma. Our product development thesis leverages femtosecond laser expertise coupled with voice of customer inputs to attain market leadership through both the technology and business model.



Meet Ora, the premier strategic partner in Ophthalmic product development

For over 40 years, Ora has proudly helped our clients earn more than 50 product approvals. We support a wide array of organisations, from small start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market.



2000+ clinical studies and consulting projects



25,000+ patients enrolled in last 7 years



Extensive, global site network



A patient centric philosophy with involvement of patient panels to optimise clinical trial delivery

Learn how to move your research forward at oraclinical.com



Moorfields Eye Charity supports the incredible and pioneering work of Moorfields Eye Hospital and its research partner, the UCL Institute of Ophthalmology. By supporting innovative research, education and care at these two institutions, we make a difference to the lives of patients at the hospital and people with sight loss around the world.

To find out more about how you can help support Moorfields, or to make a donation, visit the Moorfields Eye Charity website, contact the charity via email or telephone (020 7566 2565), or drop into our charity office at Moorfields Eye Hospital City Road.

www.moorfields.nhs.uk/eyecharity
moorfields.eyecharity@nhs.net

Registered Charity No.: 1140679

PROGRAMME COMMITTEE

Ike Ahmed | Division Head, Ophthalmology, Trillium Health Partners, Toronto, Canada. Assistant Professor, University of Toronto, Canada. Clinical Assistant Professor, University of Utah, USA.

Jorge Alio | Professor & Chairman of Ophthalmology, Miguel Hernandez University, Alicante, President, Vissum Corporation, Spain.

Gerd Auffarth | Professor & Chairman, Dept. of Ophthalmology, University of Heidelberg. Director, David J. Apple International Laboratory for Ocular Pathology, International Vision Correction Research Centre, Heidelberg, Germany.

Francesco Bandello | Full Professor & Chairman Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele of Milan, Italy.

David Chang | Altos Eye Physicians & Clinical Professor, University of California, San Francisco, USA.

Steve Charles | Founder & CEO, Charles Retina Institute Clinical Professor of Ophthalmology, University of Tennessee, USA.

Paul Chew | Professor of Ophthalmology, National University of Singapore, Singapore.

Beatrice Cochener | Professor, Chairman, Ophthalmology Department, University Hospital, Brest, France. Past-president, European Society of Cataract & Refractive Surgeons.

Jost Jonas | Professor of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg, Germany.

Sir Peng Khaw | Professor of Glaucoma & Ocular Healing, Director National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital & UCL Institute of Ophthalmology, London, UK.

Shigeru Kinoshita | Professor & Chair, Department of Ophthalmology, Kyoto Prefectural University of Medicine, Japan.

Richard Lindstrom | Founder & Attending Surgeon: Minnesota Eye Consultants, Minneapolis, USA. Adjunct Professor Emeritus: University of Minnesota, USA.

Boris Malyugin | Chief of Department of Cataract & Implant Surgery, Deputy Director General, S. Fyodorov Eye Microsurgery Complex State Institution, Moscow, Russia.

Ursula Schmidt-Erfurth | Professor and Chair, Medical University of Vienna, Austria

Prof David Spalton | Past-president, European Society of Cataract & Refractive Surgeons London, UK.

Prof Dr Ingeborg Stalmans | Head of the Glaucoma Clinic, University Hospitals UZ Leuven, Belgium. Head, Ophthalmology Research Group, University KU Leuven, Belgium.

Paulo Eduardo Stanga | London Vision Clinic Retina Lead Consultant Ophthalmologist & Vitreoretinal Surgeon. Professor of Ophthalmology & Retinal Regeneration, University of Manchester, UK.

José-Alain Sahel | Endowed Professor & Chairman, Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, USA. Professor of Ophthalmology, Sorbonne Université. Chairman Departments of Ophthalmology, Quinze-Vingts National Ophthalmology Hospital & Rothschild Ophthalmology Foundation, Paris. Director, Institut de la Vision (Sorbonne Université, Inserm, CNRS, Paris).

Ursula Schmidt-Erfurth | Professor and Chair, Medical University of Vienna, Austria

Chelvin Sng | Associate Professor, Department of Ophthalmology, National University Hospital, Singapore.

Julian D. Stevens | Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London, UK.

Donald Tan Tiang Hwee | Arthur Lim Professor, SNEC & Duke-NUS Medical School, Singapore. Partner & Senior Consultant Ophthalmic Surgeon, Eye & Retina Surgeons (ERS), Camden Medical Centre, Singapore.

Marie-Jose Tassignon | Past Chief & Chair Department of Ophthalmology Antwerp University & University Hospital Antwerp, Belgium.

Adnan Tufail | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK. Professor, UCL Institute of Ophthalmology, London, UK.

Tien Yin Wong | Founding Head & Chair Professor, Tsinghua University, Beijing, China.

ADVISORS

Laurent Attias | Senior VP, Head of Strategy, BD&L & Market Access, Alcon, USA.

Christopher Brittain | Global Head of Ophthalmology, Genentech, Burlingame, USA.

Arthur Ciociola | Vice President Global Head Regulatory Affairs GDD Ophthalmology, Devices, & Innovation, Novartis Pharma AG, Fort Worth, USA.

Eugene de Juan | Jean Kelly Stock Distinguished Chair, Ophthalmology, ForSight Labs & University of California, Menlo Park, California.

Tom Dunlap | Founder, Dunlap Ophthalmology Consulting, Board of Directors, Advisory Boards.

Malvina Eydelman | Director, Division of Ophthalmic & Ear, Nose & Throat Devices ODE/CDRH/FDA, USA.

Reza Haque | SVP and Global Head of OIC, Ophthalmic Innovation Center, Santen Santen Pharmaceutical.

Paul Hallen | Vice President & Global Head, Retina, Alcon, Texas, USA.

James Mazzo | JGlobal President Ophthalmic Devices, Carl Zeiss Meditec, USA.

Naveed Siddiqi | Novo Ventures.

ORGANISING COMMITTEE

Keith Barton | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK, Professor of Ophthalmology, UCL, UK.

Don Budenz | Professor & Chairman, Department of Ophthalmology, University of North Carolina, USA.

Lea Pietrolongo | Operational Director, Ophthalmology Futures Forums, UK.

Kuldev Singh | Professor of Ophthalmology & Director, Glaucoma Service, Stanford University Medical Center, Palo Alto, USA.

Chelvin Sng | Associate Professor, Department of Ophthalmology, National University Hospital, Singapore.

Sanny Yuzhen Jiang | Honorary Clinical Fellow, Moorfields Eye Hospital. Senior Research Associate, University College London Institute of Ophthalmology, UK.



Apellis is committed to leading the development of therapies that target the **complement system** with the goal of **slowing GA progression**.

Overactivation of the complement system is strongly associated with the development of lesions in geographic atrophy (GA).¹

Due to continuous and irreversible vision loss, there is a high unmet need to slow GA lesion progression.²

1. Katschke KJ et al. Classical and alternative complement activation on photoreceptor outer segments drives monocyte-dependent retinal atrophy *Sci Rep* 2018;8:13055.

2. Fleckenstein M et al. The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. *Ophthalmology* 2018;125:369-390.

